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Background: Early recanalization of occluded vessels in stroke is closely associated with improved clinical outcome.
Microbubble-enhanced sonothrombolysis is a promising therapy to improve recanalization rates and reduce the time
to recanalization. Testing any thrombolytic therapy requires a model of thromboembolic stroke, but to date these
models have been highly variable with regards to clot stability. Here, we developed a model of thromboembolic stroke
in rats with site-specific delivery of platelet-rich clots (PRC) to the main stem of the middle cerebral artery (MCA). This
model was used in a subsequent study to test microbubble-enhanced sonothrombolysis.
Methods: In Study 1 we investigated spontaneous recanalization rates of PRC in vivo over 4 hours and measured
infarct volumes at 24 hours. In Study 2 we investigated tPA-mediated thrombolysis and microbubble-enhanced
sonothrombolysis in this model.
Results: Study 1 demonstrated stable occlusion out to 4 hours in 5 of 7 rats. Two rats spontaneously recanalized at
40 and 70 minutes post-embolism. Infarct volumes were not significantly different in recanalized rats, 43.93 ± 15.44%
of the ischemic hemisphere, compared to 48.93 ± 3.9% in non-recanalized animals (p = 0.7). In Study 2, recanalization
was not observed in any of the groups post-treatment.
Conclusions: Site specific delivery of platelet rich clots to the MCA origin resulted in high rates of MCA occlusion, low
rates of spontaneous clot lysis and large infarction. These platelet rich clots were highly resistant to tPA with or without
microbubble-enhanced sonothrombolysis. This resistance of platelet rich clots to enhanced thrombolysis may explain
recanalization failures clinically and should be an impetus to better clot-type identification and alternative recanalization
methods.
Keywords: Embolic Stroke, Microbubbles, Platelet Rich Clot, Rat, Thrombolysis, Ultrasound, SonothrombolysisBackground
Currently, the only approved thrombolytic treatment for
acute ischemic stroke is recombinant tissue plasminogen
activator (tPA) delivered intravenously within 4.5 hours
of stroke onset [1]. However, less than 10% of all ische-
mic stroke patients are eligible for therapy [2] and tPA
achieves successful recanalization in less than half of
those treated [3]. Achieving higher recanalization rates* Correspondence: Max.Nedelmann@neuro.med.uni-giessen.de;
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unless otherwise stated.in a timely manner is a key goal to developing better
stroke thrombolytic therapy.
Use of ultrasound to enhance recanalization with tPA is
a promising approach. The first clinical report of stroke
sonothrombolysis indicated increased rates of recanaliza-
tion in patients receiving continuous transcranial Doppler
ultrasound (TCD) monitoring during tPA therapy [4]. Sev-
eral small clinical trials with perflutren-lipid and galactose-
based microbubbles as enhancers of sonothrombolysis sug-
gest that microbubbles may produce further improvements
in the rates of recanalization [5-8]. Despite the promise of
this therapy, more than half of patients treated do not re-
canalize [9] and concerns have been raised regarding itsl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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[6,10]. Therefore, there is still a great need for pre-clinical
studies to better understand the efficacy, mechanisms and
safety effects of this potential therapeutic strategy.
To test any thrombolytic therapy, a model of stroke is
required that uses a life-like clot to block major cerebral
arteries. Current thromboembolic models are highly vari-
able and it is likely that this variability is related to the
choice of clot and its inherent stability with regards to
spontaneous and thrombolytic-induced lysis. Recent stud-
ies have demonstrated that platelet-rich clots (PRC) are
more stable in vitro than other clot variations and are also
more similar to clots retrieved from human stroke patients
histologically [11]. These clots have yet to be tested in vivo
and during sonothrombolysis.
In this article we describe a method of embolic stroke
using site-specific delivery of a PRC to the origin of the
middle cerebral artery (MCA). Two separate studies
were performed. In study 1 our aim was to investigate
rates of spontaneous recanalization and infarct volumes
using our new PRC model. In study 2 we aimed to inves-
tigate the effect on recanalization rates of tPA therapy
alone or in conjunction with ultrasound and a new
microbubble formulation (BR38) in this model.
Methods
Animals
All animal experimentation was carried out in accordance
with local legislation. Experiments conducted at the
University of Newcastle, Australia (UoN) were in accord-
ance with Animal Care and Ethics Committee (ACEC)
guidelines (approval # A-2010-128) and in compliance
with the requirements of the Australian Code of Practice
for the Care and Use of Animals for Scientific Purposes.
Experiments conducted at Justus-Liebig University Giessen,
Germany (JLU), were in accordance with the German ani-
mal protection legislation and approved by the regional
ethics committee (Az. B2/257). At UoN, spontaneouslyTable 1 Experimental protocols
Study 1
Location Newcastle, Australia
Aim Develop model, Determine spontaneous
rate
Primary Outcome [method] Recanalization [Laser Doppler]
Secondary Outcome(s)
[method]
Infarct Volumes [TTC], Mortality, Neurolo
Survival post-embolism 24 h
Treatment groups (n) No treatment (n = 7)
Laser Doppler Monitoring Continuous
To 4 h post-embolismhypertensive rats (SHR) aged 14–18 weeks and weighing
320-375 g, were sourced from Animal Resources Centre,
Perth, Australia. At JLU, 15–21 weeks old SHR weighing
290-375 g were sourced from Harlan laboratories GmbH,
Netherlands. Surgeries were performed at both centres by
the same investigator (AT). Anaesthesia was induced with
5% isoflurane and maintained at 1.5-3% in oxygen and ni-
trogen (2:1). Temperature was monitored and maintained
at 37°C throughout all experiments. SpO2 and heart rate
were also monitored at UoN (Study 1).
Experimental design
Study 1 was performed to determine spontaneous recana-
lization rates in the first 4 hours post-embolism, and
24 hour infarction volume and mortality (n = 14; per-
formed at UoN). In Study 2 we investigated the effect of
tPA or tPA + ultrasound + BR38 microbubbles compared
to saline control in this model (n = 44; performed at JLU).
The specifics of each protocol are outlined in Table 1.
Clot preparation was modified from the methods of
Roessler et al. [11]. Briefly, cardiac blood from donor ani-
mals (Study 1: n = 4, Study 2: n = 10) was collected with
sodium citrate anticoagulant (3.2%; blood:citrate = 9:1)
and underwent 2-step centrifugation to obtain platelet rich
plasma. Whole plasma and buffy coat were collected after
an initial spin (15 minutes at 180 g). The platelet-rich
plasma layer and buffy coat were collected after a second
fast spin (20 minutes at 1500 g). PRC formation was initi-
ated by recalcification of the platelet rich plasma + buffy
coat with CaCl2 (20 mM final concentration). The sample
was drawn into a 40 cm length of PE-50 tubing (40 cm,
i.d. 0.58 mm) and clamped at one end. Using an air filled
syringe, pressure was forced into the unclamped end of
the catheter to create clots of consistent size. This end
was then also clamped to retain the pressure and incu-
bated at 37°C for 2 hours. The resultant clot was ejected
into a dish of saline and stored at 4°C overnight. Clot
preparation was the same for both studies, with theStudy 2
Bad Nauheim, Germany
recanalization Determine recanalization rates with microbubble +
sonothrombolysis enhancement of tPA
Recanalization [Laser Doppler]
gical Deficit scores Clot lysis [Inspection of the major branches of the
cerebral arterial circulation]
2 h
Saline (n = 10), tPA (n = 10), tPA + Ultrasound + BR38
microbubbles (n = 10)
Discontinuous
Pre-embolism, Post-embolism, Pre-treatment, Post-treatment
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5 minutes in Evans blue for visualisation within major
branches of the cerebral arterial circulation at sacrifice.
The method of site-specific clot delivery was based on
the method of MCA thread occlusion we use routinely
[12-14] with catheter placement and clot delivery as de-
scribed by DiNapoli et al. [15]. Briefly, a modified cath-
eter (PE-8, o.d. 0.35 mm, connected to silastic tubing)
containing a 30 mm length of PRC was inserted into the
internal carotid artery via the external carotid artery. It
was advanced until a sensation of mild resistance indi-
cated the tip was at the middle cerebral artery (MCA)
origin, then retracted 1–2 mm to restore flow to the
MCA allowing site-specific clot injection. The clot was
injected with 30–50 μl saline and the catheter left in
place for 10 minutes to allow the clot to stabilize. The
catheter was then completely removed from the vessel
and the surgical site sealed.
Confirmation of occlusion and recanalization rates
In both studies, confirmation of occlusion of the MCA
after clot injection was made by laser Doppler Flowme-
try (LDF). Occlusion was defined as a reduction to < 50%
from baseline values of regional cerebral blood flow
(rCBF). The primary outcome of both studies was recan-
alization rates. Recanalization was defined as a return
to ≥ 100% of baseline rCBF. Two methods of LDF moni-
toring were used: continuous and discontinuous.
Study 1
Continuous laser Doppler tissue perfusion monitoring was
performed using a single fibre optic probe (MoorVMS-LDF
with probe type VP10M200ST, Moor instruments, UK). A
longitudinal incision was made along the scalp, above the
midline and over bregma. The skull was thinned using a
dental drill 1 mm posterior to bregma and as far lateral as
possible (at the border of the temporalis muscle). The
Doppler probe was affixed to the skull within a silicone
probe holder. The position of the probe was inspected
under the operating microscope before fixation to ensure it
was not placed over large vessels that would otherwise
compromise the accuracy of the readings. The recordings
were taken for a minimum 20 minutes pre-embolism.
Baseline rCBF was calculated as the average of a 5 minute
period immediately prior to clot injection. All subsequent
readings were expressed as a percentage of baseline. Con-
tinuous LDF monitoring also allowed confirmation of the
initial MCA occlusion by the clot delivery catheter, followed
by catheter retraction (restoring flow) and clot injection.
LDF monitoring continued for the duration of observation
under anaesthesia (4 hours post-embolism). Four hours of
post-occlusion monitoring was based on the approved time
window for clinical tPA administration to determine if
these clots were stable during that period. Clinical benefitof thrombolysis beyond this time is limited [16]. Animals
were then woken and returned to their cages until sacrifice
at 24 hours for infarct volume analysis.
Study 2
Continuous monitoring could not be performed during
ultrasound treatment for Study 2 due to the apparatus
set-up, so a discontinuous approach was used [17]. Dis-
continuous monitoring was performed at 4 time points:
pre-embolism (−30 minutes), post-embolism (10 minutes),
pre-treatment (50 minutes) and post-treatment (130 mi-
nutes), using an Oxyflo2000 Microvascular Perfusion Moni-
tor with Oxyflo XP Probe 17 mm diameter (MNP 100XP-3/
15, Oxford Optronix, UK). Recordings were made as per
Soehle et al. [17]. Animals were sacrificed after final LDF
recording for visual inspection of clot presence.
Treatment groups
Animals in Study 2 received intravenous injections via
the tail vein of either tPA, tPA and microbubbles, or
vehicle (saline) started 1 hour after embolism (n = 10
per group). The tPA and microbubble group also re-
ceived 60 minutes ultrasound. tPA (10 mg/kg; Actilyse™,
Boehringer Ingelheim, Ingelheim, Germany) was delivered
as a 10% bolus and the remainder delivered over 1 hour.
Total injected volume was 2.4 ml. The dose of 10 mg/kg
was used based on evidence that the rat fibrinolytic system
is 10-fold less sensitive than humans [18]. A total of four
0.1 ml doses of BR38 microbubbles (Bracco Research,
Switzerland) at a concentration of 4 × 108 bubbles/ml
(10 μl BR38 diluted in 90 μl NaCl), were delivered at
15 minute intervals starting with the initial tPA bolus.
BR38 are 35% perfluorobutane and 65% nitrogen in a
phospholipid shell. The dose of BR38 was comparable to
previously calculated doses of other microbubble formula-
tions [19]. Transcranial colour-coded Duplex ultrasound
(TCCD) was applied continuously for the duration of
treatment (60 minutes). A 3 MHz diagnostic ultrasound
probe was placed 40 mm above the skull (B-mode, color-
Doppler functions switched on, maximum output (mech-
anical index of 1.7)) (Sonos 7500; Philips Ultrasound,
USA). The distance between the skull and ultrasonic
probe was bridged with ultrasound gel (Sonosid®; Asid
Bonz, Germany) in a plastic cylinder open at both ends
and the beam was aligned to expose the entire brain in-
corporating the circle of Willis and the occluded MCA
(spectral Doppler sample volume placed in the midbrain
(57 mm)).
Additional outcomes
For both studies, the primary outcome was LDF recanali-
zation. Secondary outcomes were infarct volume, neuro-
logical deficit and mortality for Study 1, and visualization
of PRC in the MCA post-mortem for Study 2.
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a series of neurological tests were performed to determine
level of functional deficit following stroke. Deficit was
assessed by an observer blinded to recanalization outcome
with a modified Bederson scoring system [20,21], scoring
the degree of flexion of the affected limb, degree of twist-
ing of the animal’s torso, and the ability to brace against a
lateral force. Each test was given a score of 0, 1, or 2 where
0 = not affected and 2 = severely affected. These scores
were totalled for a final score between 0 and 6. Mobility
was also scored, 0 =mobile and 2 = immobile.
Infarction was assessed at 24 hours in Study 1. Animals
were sacrificed by isoflurane followed by cardiac perfusion
with cold saline (3 minutes, Peri-Star™ Pro perfusion
pump, World Precision Instruments, USA). Brains were
removed and placed in cold saline (4°C), stirred gently
with a magnetic stirrer. Brain slices (2 mm) were covered
in 1% 2,3,5-triphenyl-tetrazolium chloride (TTC) solution
and incubated at 37°C for 10 minutes. Slices were turned
and covered in fresh TTC for a further 10 minutes at
37°C, stored overnight at room temperature in buffered
formalin then photographed. Hemispheres and regions
of infarct were traced using ImageJ software and infarct
volumes were calculated by averaging the area of the
top of the section and the area of the base of a section
and multiplying by the width (volume of a trapezoid).
The total infarct volume was the sum of all slices. In-
farct volumes were expressed as a percentage of the ip-
silateral hemisphere.
Arterial filling and clot visualisation in Study 2 was
achieved by intravascular silicone infusion (Figure 1).
Animals were sacrificed immediately following post-
treatment LDF (130 minutes), and Microfil (Flow Tech,
Inc., USA) was used to cast the vasculature, as previ-
ously described [19]. Briefly, the circulation was flushed
with saline until the venous effluent was clear of blood.Figure 1 Visualisation of vascular filling and clot presence (Study 2). V
the vasculature and clot presence (black). All animals had clot in the major
view of the Circle of Willis, (B) shows the lateral surface of the right hemisp
cerebral artery (ACA) and internal carotid artery (ICA). Images of all brains cThe descending aorta, subclavian arteries and both left
and right external carotid arteries were ligated and Micro-
fil, prepared to manufacturer’s instructions, was injected
via the aortic arch to fill the arterial and venous cerebral
circulation via internal carotid and vertebral arteries. Dur-
ing the injection process, excessive dilation of the aorta
was avoided so as to maintain physiological pressure con-
ditions. After 45 minutes, the Microfil formed an elasto-
meric gel at room temperature and the brain was removed
from the skull and immersed in formalin. The Circle of
Willis and the lateral surfaces of the brain were photo-
graphed for visualisation of clot presence.
Inclusion/exclusion criteria
Pre-specified exclusion criteria were as follows: No appro-
priate LDF drop after clot injection (Study 1 & 2); spontan-
eous recanalization pre-treatment (Study 2); Subarachnoid
hemorrhage (SAH) due incorrect catheter insertion was
identified during continuous LDF monitoring (Study 1)
or post-mortem (Study 1 & 2). Excluded animals in
study 2 were replaced so that treatment groups con-
tained 10 animals.
Statistical analysis
Data is presented as mean ± standard deviation (SD). Dif-
ferences in infarct volumes between recanalized and non-
recanalized animals were assessed with unpaired Student’s
t-test. Statistical significance was considered to be a
p-value < 0.05.
Results
Study 1 – Investigation of the Model
Three animals were excluded from analysis due to either
SAH (n = 1) or occlusion not confirmed by LDF (n = 2).
SAH was identified by LDF signal and confirmed post-
mortem. One animal died overnight post-embolism.essels were perfused post-mortem with Microfil (yellow) to visualise
cerebral vessels after treatment. (A) Shows the vasculature from the
here. Vessels labelled are: middle cerebral artery (MCA), anterior
an be viewed in the Additional file 1.
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likely cause of death. This animal was included in LDF
analysis, but not infarct calculations or neuroscoring.
Five of seven animals remained occluded for the duration
of LDF monitoring (4 hours post-embolism) (Figure 2A).
Two animals spontaneously recanalized at 40 and 70 mi-
nutes post-embolism (Figure 2B). Infarct volumes were
48.93 ± 3.9% and 43.93 ± 15.44% of hemisphere in non-
recanalized and recanalized rats, respectively. There was
no statistical significance between groups (p = 0.7), how-
ever the rat that recanalized earlier (40 minutes) had a
smaller infarct than the one that recanalized later (70 -
minutes): 33.01% v. 54.85% of hemisphere, respectively.
Neuroscores at 24 hours were 3 ± 2. All animals exhibited
a neurological deficit.
Study 2 - Thrombolytic treatment effect
A total of 4 animals were excluded due to SAH (n = 2, de-
termined post-mortem), excessive bleeding pre-embolism
(n = 1), and catheter dislodgement during treatment (n = 1).
These animals were replaced so that all groups consisted of
10 animals. No animals recanalized in any treatment groupFigure 2 Laser Doppler flowmetry and infarction following middle ce
seven rats had successful embolization of the MCA. (A) Five rats remained
died overnight and was not included in TTC assessment of infarct. (B) Two
(raw data).in Study 2 (Figure 3 and see Additional file 1). Clot was
visible within the Circle of Willis of all animals except
one in the ultrasound group, however clot was observed in
the distal MCA of this animal (Figure 1 and see Additional
file 1).
Discussion
We present here an experimental model of embolic stroke
using PRC. This model was developed because clots re-
trieved from patients often have high platelet concentra-
tions [22-25], unlike most commonly used experimental
clots, which are red cell or fibrin-rich [11]. We have
shown the experimental PRC to be highly resistant to
spontaneous and tPA-mediated thrombolysis with or
without enhancement with microbubble-enhanced sono-
thrombolysis. This high resistance to lysis suggests that
greater levels of platelets may be an important contribut-
ing factor to failed recanalization in many stroke patients
despite tPA treatment.
Our findings confirmed PRC resistance to thromboly-
sis with tPA, and indicate that clots enriched with plate-
lets are highly resistant to lysis, even with the additionrebral artery occlusion with platelet rich clots (Study 1). A total of
occluded for the duration of LDF observation (mean ± SD). One rat
rats recanalized at 40 min (black trace) and 70 min (grey trace)
Figure 3 Laser Doppler flowmetry (LDF) of regional cerebral blood flow in treatment groups (Study 2). Animals underwent embolization
of the middle cerebral artery (MCA) with platelet rich clot. LDF confirmed occlusion in all animals and indicated no recanalization post-treatment.
Data represents the mean of n = 10 per group. There were no significant differences between groups. (U/S = ultrasound; BR38 =microbubbles).
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work of a PRC clot, large platelet aggregates are ob-
served. These aggregates lead to increased rigidity of the
clot and significantly increase time to tPA-induced lysis
compared with other clots [11,26]. Histological compari-
sons of experimental PRC with clots retrieved from hu-
man stroke patients have also revealed both to contain a
strong cross-linked fibrin mesh that ensures mechanical
stability [11]. The addition of platelets to thrombin-
induced clots also increases their resistance to thromb-
olysis in vivo [27]. A major inhibitor of plasminogen
activation is plasminogen activator inhibitor (PAI-1) re-
leased locally by platelets and vascular endothelial cells.
PAI-1 has been implicated as increasing PRC resistance
to tPA lysis [28,29].
There are several putative mechanisms for the action
of sonothrombolysis. These include microstreaming of
blood, that enhances access of tPA into the clot, and
mechanical disruption of the fibrin mesh [30]. Our re-
sults showed that microbubble-enhanced sonothrombo-
lysis was insufficient to lyse thrombi highly enriched in
platelets and this may be an important consideration
when delivering reperfusion therapy to patients. While
sonothrombolysis appears to enhance recanalization
rates in stroke patients, there is a subset of patients (33–
59%) who do not achieve complete recanalization des-
pite the addition of sonothrombolysis with or without
microbubbles [6,8,9,31]. Clot composition in this sub-
group is not known, however from studies of mechanic-
ally retrieved thrombi from stroke patients we do know
that they are very heterogenous and high platelet levels
occur frequently in clinical stroke [22-25]. Moreover it
has been shown, that clot composition is correlated with
outcome after 90 days [32]. Our data suggest a likelyexplanation for at least some of these patients with fail-
ure of recanalization is PRC resistance to thrombolysis.
If this is the case, alternative approaches will be needed.
Stroke is a heterogeneous condition with no two clots
compositionally the same [24] thereby resulting in differ-
ing efficacies of tPA thrombolysis. The majority of pre-
clinical in vivo studies do not directly compare clot
types. Investigating only one clot type is also a limitation
of our study. However, in vitro work of PRC has shown
greater resistance to thrombolysis than other clot types
[11,26], with a recent study demonstrating increased tPA
resistance with increasing platelet counts [33]. PRC are
also better histological mimics of clinical thrombi re-
trieved from stroke patients who failed to recanalize
after tPA therapy. Our study confirms PRC resistance to
tPA thrombolysis in an in vivo rat model and also dem-
onstrates resistance to enhanced sonothrombolysis.
Studies of sonothrombolysis in rat models are surpris-
ingly lacking. Most have used low frequency ultrasound
or were not performed in embolic models. Studies of
10 mg/kg tPA thrombolysis in rat embolic MCA occlu-
sion models are the closest comparisons we can achieve,
and only a few report recanalization. Spontaneously
formed clots with high erythrocyte content as well as
thrombin induced-fibrin rich clots recanalize in >80% of
cases [34-36]. These experimental clots may mimic the
clots of tPA responders, but does not allow room for
testing thrombolytic enhancers. Since no recanalization
was observed in our study, it is reasonable to conclude
that the composition of our clots has a large effect on
thrombolysis. The lack of preclinical studies comparing
clots, or studying sonothrombolysis at diagnostic fre-
quencies clearly highlights a gap in our knowledge of the
full impact of clot type on sonothrombolysis in vivo. It
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enhanced sonothrombolysis, a large proportion of patients
still do not respond to therapy [37]. Our study could pro-
vide one answer to this – that the occluding thromboem-
boli of these patients contain high proportions of platelets.
An important implication of these findings is that there
may be a subset of patients with PRC and even the com-
bination of ultrasound with tPA may be largely futile to
cause recanalization. The clinical risk of haemorrhage with
increasing tPA doses prevents testing higher doses to de-
termine if thrombolytic recanalization can be achieved at
all in this clot type. The dose of tPA we used (10 mg/kg) is
already a high dose, with studies of other clot types sug-
gesting that the clinical dose is a better mimic of the clin-
ical response to recanalization [38]. Further increasing our
tPA dose would unlikely exhibit significant increases in re-
canalization and a more clinically relevant interpretation
of these results is that PRC do not lyse solely by the fi-
brinolytic mechanisms initiated by tPA and ultrasound.
Early identification of patients with clots of higher platelet
content might allow time to pursue alternative approaches
to reperfusion, such as mechanical clot retrieval. Another
consideration is the use of antiplatelet agents. Both GPIIb/
IIIa receptor blockers (abciximab) and cyclo-oxygenase in-
hibitors (aspirin) have shown promise in reducing clot
lysis time and causing decreases in platelet-fibrin aggre-
gates when applied prior to clot formation. Reduced clot
lysis time has been observed when abciximab is added to
pre-established clots [26], suggesting a possible thera-
peutic strategy. There is certainly promise in using com-
bination antiplatelet -tPA therapy, however there is
clinical concern regarding the risk of additional bleeding
complications in stroke patients [39,40]. Several imaging
approaches have been used to try and identify resistance
of clots to thrombolysis. MRI and CT studies of experi-
mental and clinical stroke clots have begun to correlate
signal intensities with composition of red cells and fibrin
[23,25,41-43]. So far, studies have been able to identify red
cell rich clots from other clot types, due to the presence of
iron in these cells that increases signal intensity. Clots high
in red cells were shown to be more easily lysed [11]. How-
ever the current study indicates that platelet content may
be a key factor affecting recanalization rates. As yet, the
ability to distinguish fibrin-rich from platelet-rich clots is
limited.
A limitation of this study is that we did not assess haem-
orrhage, a known complication of sonothrombolysis [37].
Clinical evidence suggests that TCCD may cause higher
rates of haemorrhage than TCD monitoring [37]. We have
previously demonstrated efficacy of microvascular recanali-
zation using this system and parameters, and with ultra-
sound. Intracerebral haemorrhage was observed in only 1 of
25 animals treated with tPA + ultrasound + microbubbles,
and this protocol was deemed safe for sonothrombolysis[19]. All clinical sonothrombolysis studies using TCCD
have used ultrasound insonation durations of 60 minutes
[31,44,45], which was our choice for this study. Yet the
majority of TCD studies have insonated for 2 hours
[6,7,9,46]. Increasing insonation duration may result in
greater recanalization rates, but this direct comparison
has not been investigated clinically and it is unknown what
the optimal duration is for maximal efficacy with minimal
adverse events. Given the clinical evidence of increased
haemorrhage with TCCD, any study of longer duration
insonation should consider safety as an important outcome.
Our ability to determine the efficacy of BR38 micro-
bubbles to enhance sonothrombolysis was limited in this
study. BR38 microbubbles were developed to improve
on the existing SonoVue™ formulation and are more
stable and circulate longer in the microcirculation [47].
A previous study showed that BR38 enhanced sono-
thrombolysis of spontaneously formed thrombi [48], a
relatively easy to lyse clot type [49,50]. Our decision not
to include a sonothrombolysis group without microbub-
bles was made because such experiments with diagnostic
frequencies and BR38 microbubbles have not been per-
formed in rats. There is sufficient evidence that microbub-
bles have greater efficacy than ultrasound + tPA alone
[37]. Therefore, we chose to determine maximal effect
with these bubbles, while limiting animal numbers for eth-
ical reasons. Had an effect between groups been observed,
it would have warranted further study to determine the
exact effect of these microbubbles. However the PRC gen-
erated in the current study ‘overshot the mark’ and proved
completely resistant to lysis, regardless of treatment.
Conclusion
Here we sought to create clots more resistant to lysis to
increase the rigor of thrombolytic testing. However, this
model appears to have gone too far in the other direc-
tion and has created clots that are highly resistant to
even enhanced lysis with tPA, ultrasound and microbub-
bles. Sonothrombolysis has previously been shown to be
effective in embolic models of stroke with different clot
types [51-53] but our study suggests that PRC are par-
ticularly resistant to thrombolysis even with the combin-
ation of tPA, sonothrombolysis and microbubbles. Our
experimental PRC may be representative of clots seen in
a subset of stroke patients who are unresponsive to con-
ventional thrombolytic therapies. If so, imaging ap-
proaches to identify such clots may allow early pursuit
of alternative methods such as mechanical clot retrieval.
These clots could also provide a model for development
of more rigorous therapies for these patients. Our study
highlights the importance of clot structure on the effi-
cacy of thrombolytic therapy and suggests a need for
further investigation of in situ identification of clot
structure to tailor treatment to the patient.
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Additional file 1: Vascular filling and clot presence (Study 2).
Description of Data: Vessels were perfused post-mortem with Microfil
(yellow) to visualise the vasculature and clot presence (black). All animals
are presented. (A) shows the vasculature from the view of the circle of
willis, (B) shows the corresponding lateral surface of the right hemisphere.
Vessels labelled are: middle cerebral artery (MCA), anterior cerebral artery
(ACA) and internal carotid artery (ICA). Images of all brains can be viewed
in the supplemental data. Treatment groups were saline, tPA or ultrasound
insonation with tPA and BR38 microbubbles (U/S + tPA + BR38).
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